FDA Grants Accelerated Approval For Bladder Cancer Drug
Padcev is the first FDA approved treatment in the US for patients with advanced or metastatic urothelial cancer.
The drug will treat patients with advanced bladder cancer, reports Reuters.
It is for when the disease has progressed even after immunotherapy and chemotherapy.
The American Cancer Society estimates 17,670 people will die from bladder cancer in the US this year.
The continued approval of the drug may depend upon verification of clinical benefit in confirmatory trials.